A newly developed drug, daraxonrasib, has shown promise in doubling the lifespan for pancreatic cancer patients. However, it is not a cure and is only effective when the cancer is diagnosed and treated early.

The newly developed treatment daraxonrasib can double the years left to live for patients with pancreatic cancer — but it doesn't cure the disease and only works if the cancer is treated early.